CorMedix Inc. filed a Form 8-K on November 2, 2026, disclosing a press release that provided a business update and announced the company's cash position for the quarter ended September 30, 2026.

Key Highlights

  • Filing date: The current report was filed and dated November 2, 2026, the same date as the earliest event reported.
  • Reporting period: The cash position disclosure covers the quarter ended September 30, 2026.
  • Dual item disclosure: The filing invokes both Item 2.02 (Results of Operations and Financial Condition) and Item 7.01 (Regulation FD Disclosure), both referencing the same Exhibit 99.1 press release.
  • Exhibit furnished: The press release, dated November 2, 2026, is furnished as Exhibit 99.1 and is not deemed "filed" for purposes of Section 18 of the Exchange Act.
  • Signed by: Joseph Todisco, Chief Executive Officer of CorMedix Inc., signed the filing on November 2, 2026.
  • Forward-looking statements: The filing contains forward-looking statements, including references to 2027 post-TDAPA Add-on changes for DefenCath and related forecasts, which the company cautions are subject to risks and uncertainties.

CorMedix Furnishes Q3 2026 Cash and Business Update Under Items 2.02 and 7.01

CorMedix Inc. (NASDAQ:CRMD), a Delaware-incorporated pharmaceutical company headquartered in Parsippany, NJ, filed this Form 8-K with the SEC on November 2, 2026. According to the filing, the company issued a press release on that same date announcing its cash position for the quarter ended September 30, 2026, along with a broader business update. The press release is attached as Exhibit 99.1 and is described as "furnished" rather than "filed," meaning it is not subject to the liabilities of Section 18 of the Securities Exchange Act of 1934 and is not automatically incorporated by reference into other regulatory filings.

The filing invokes two separate disclosure items: Item 2.02, covering results of operations and financial condition, and Item 7.01, covering Regulation FD. Both items reference the same Exhibit 99.1 press release. The company notes that any incorporation by reference would require a specific reference in the relevant filing.

The filing also includes forward-looking statements, which the company attributes to its own management expectations. These include references to "the 2027 post-TDAPA Add-on changes for DefenCath" and "CorMedix's forecasts and projections for the 2027 Add-on trajectory." The company cautions that actual results may differ materially from these projections, citing factors such as changes in customer utilization patterns, pricing, and differences in CMS calculation methodology. The filing directs readers to risk factors in CorMedix's most recent Annual Report on Form 10-K and subsequent quarterly and current reports.

What Was Disclosed

CorMedix filed a Form 8-K on November 2, 2026, furnishing a press release as Exhibit 99.1 that announced the company's cash position for the quarter ended September 30, 2026, along with a business update, under Items 2.02 and 7.01.